BioSpace News Archive

Sonoma Pharmaceuticals, Inc. today announced the expansion of its Microcyn Negative-Pressure Wound Therapy (NPWT) Solution products in the United States.

Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i ® , Scientist.com’s Supplier Pre-assessment Program.

Proprio today announced a landmark multi-phase partnership with the Biedermann Group, the prominent innovator in next generation spinal implants with Proprio’s Paradigm system, which harnesses AI, computer vision, and augmented reality to provide unprecedented real-time visualization and guidance to surgeons in the operating room.

Mainz Biomed N.V., a leader in molecular genetics diagnostic solutions for early cancer detection, announced financial results for the fiscal year ended December 31, 2023.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024.

Galectin Therapeutics, Inc. reported the positive outcome of its fifth independent data and safety monitoring board meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with cirrhotic portal hypertension caused by Metabolic Dysfunction-Associated SteatoHepatitis.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test.

NewAmsterdam Pharma Company N.V. announced that it has met the enrollment target of 9,000 patients for the pivotal Phase 3 PREVAIL cardiovascular outcomes trial evaluating obicetrapib in adult patients with a history of atherosclerotic cardiovascular disease, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced that collaborators at the Beth Israel Deaconess Medical Center (BIDMC) at Havard Medical presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting demonstrating that TPST-1120 reduces kidney cancer (RCC) growth as a monotherapy, while also showing increased inhibition when combined with frontline chemotherapy and immunotherapy.